Ezetimibe

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5163 publications

Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy.

Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering Therapy.

Journal: JAMA

Published: April 08, 2026

Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data.

Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data.

Journal: Journal of the American Heart Association

Published: April 07, 2026

Obecetrapib, CETP Inhibition, and Atherosclerosis: There Is Light at the End of the Tunnel.

Obecetrapib, CETP Inhibition, and Atherosclerosis: There Is Light at the End of the Tunnel.

Journal: Journal of lipid research

Published: March 27, 2026

Moderate-intensity statin plus ezetimibe: time to rethink it as an optimal initial lipid-lowering strategy

Moderate-intensity statin plus ezetimibe: time to rethink it as an optimal initial lipid-lowering strategy

Journal: Zhonghua xin xue guan bing za zhi

Published: March 22, 2026

Statin prescription rates for prevention of atherosclerotic cardiovascular disease in adults 40-75 years old with type 1 diabetes.

Statin prescription rates for prevention of atherosclerotic cardiovascular disease in adults 40-75 years old with type 1 diabetes.

Journal: BMJ open

Published: March 20, 2026

Early LDL-C Lowering Efficacy of High-intensity Atorvastatin and Ezetimibe Combination Compared with High-intensity Atorvastatin Alone in Acute Coronary Syndrome: The LAI EARLY ACS Study.

Early LDL-C Lowering Efficacy of High-intensity Atorvastatin and Ezetimibe Combination Compared with High-intensity Atorvastatin Alone in Acute Coronary Syndrome: The LAI EARLY ACS Study.

Journal: The Journal of the Association of Physicians of India

Published: March 12, 2026

Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemia.

Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemia.

Journal: Expert opinion on pharmacotherapy

Published: March 05, 2026

Ezetimibe alone for over 75 years old as a primary prevention to decrease cardiovascular events.

Ezetimibe alone for over 75 years old as a primary prevention to decrease cardiovascular events.

Journal: Annals of medicine

Published: February 24, 2026

Ten Reasons to Treat All Individuals with a Positive Coronary Artery Calcium Score.

Ten Reasons to Treat All Individuals with a Positive Coronary Artery Calcium Score.

Journal: The American journal of medicine

Published: February 20, 2026

Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation.

Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation.

Journal: EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

Published: February 16, 2026

LDL-CHOLESTEROL LOWERING WITH ATORVASTATIN, ROSUVASTATIN AND SIMVASTATIN: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY.

LDL-CHOLESTEROL LOWERING WITH ATORVASTATIN, ROSUVASTATIN AND SIMVASTATIN: RESULTS OF A RETROSPECTIVE OBSERVATIONAL STUDY.

Journal: Georgian medical news

Published: February 13, 2026

Advanced therapy in familial hypercholesterolemia.

Advanced therapy in familial hypercholesterolemia.

Journal: Canadian family physician Medecin de famille canadien

Published: February 12, 2026

Showing 1-12 of 5,163

Last Updated: 04/28/2026